Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for PTN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 0.0975M
December 31, 2025 0.1291M
September 30, 2025 0.00
June 30, 2025 0.034M
March 31, 2025 0.0672M
December 31, 2024 0.1001M
September 30, 2024 0.1509M
June 30, 2024 0.2098M
March 31, 2024 0.3353M
December 31, 2023 0.4576M
September 30, 2023 0.6074M
June 30, 2023 0.6967M
March 31, 2023 0.4986M
December 31, 2022 0.5837M
September 30, 2022 0.6937M
June 30, 2022 0.7827M
March 31, 2022 0.8994M
December 31, 2021 1.018M
September 30, 2021 0.8088M
June 30, 2021 0.9005M
March 31, 2021 0.9862M
December 31, 2020 0.8556M
September 30, 2020 0.9118M
June 30, 2020 0.9533M
March 31, 2020 0.00
Date Value
December 31, 2019 0.00
September 30, 2019 0.00
June 30, 2019 0.3329M
March 31, 2019 1.329M
December 31, 2018 2.321M
September 30, 2018 4.305M
June 30, 2018 6.282M
March 31, 2018 8.25M
December 31, 2017 10.21M
September 30, 2017 12.17M
June 30, 2017 14.12M
March 31, 2017 16.06M
December 31, 2016 17.67M
September 30, 2016 18.60M
June 30, 2016 19.72M
March 31, 2016 19.67M
December 31, 2015 19.63M
September 30, 2015 19.59M
June 30, 2015 9.849M
March 31, 2015 9.832M
December 31, 2014 9.814M
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.002M
December 31, 2013 0.0081M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Decoy Therapeutics, Inc. 0.00
ACADIA Pharmaceuticals, Inc. 59.55M
Alnylam Pharmaceuticals, Inc. 2.942B
Anika Therapeutics, Inc. 23.32M
Savara, Inc. 30.11M